The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Johnson & Johnson (NYSE:JNJ) is the easiest healthcare sanction to measure connected the committee heading into its July 15 net release, and the setup leaves small to debate. The banal has already told you what it thinks of the fundamentals, rising astir 25% twelvemonth to day and astir 66% implicit the past year. Yet the net power, the dividend and the pipeline inactive warrant stepping successful earlier the net report.

Johnson & Johnson walked into 2026 with wide acceleration. Q1 gross deed $24.06 billion, up 9.9% twelvemonth implicit year, and adjusted EPS of $2.70 marked the 4th consecutive beat. Innovative Medicine grew 11.2% adjacent with STELARA down 59.7%, due to the fact that TREMFYA jumped 68.3%, DARZALEX roseate 22.5% and CARVYKTI surged 62.1%. Management raised full-year guidance to $100.30B to $101.30B successful gross and $11.45 to $11.65 successful adjusted EPS, and CEO Joaquin Duato told investors JNJ is "delivering connected its committedness for a twelvemonth of accelerated maturation and impact."

The Income Case Writes Itself

Dividend Kings bash not spell connected merchantability often. JNJ has present raised its payout for 64 consecutive years, with the astir caller hike of 3.1% pushing the quarterly to $1.34 per share. Backing that cheque is $19.7 cardinal successful FY2025 escaped currency travel and $26.80 cardinal successful nett income, which grew 90.56%. This is durable status income astatine scale, and a $634.06 cardinal equilibrium expanse backing it up.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Johnson & Johnson didn't marque the cut. Grab the names FREE today.

The Catalyst Is Priced, but Not Fully

Polymarket traders are pricing a 92% probability that JNJ beats its Q2 fig connected July 15, with MedTech carrying an 88% probability of clearing $8.8 billion. Beyond the net report, the pipeline offers existent optionality: ICOTYDE FDA approval, the TECVAYLI + DARZALEX FASPRO combo, and the planned DePuy Synthes orthopaedics separation that unclutters the multiple. Wall Street is aligned: 15 Buy ratings against conscionable 1 Sell rating.